| scholarly article | Q13442814 |
| P50 | author | Joachim Morschhäuser | Q89087588 |
| Ramin Homayouni | Q71582235 | ||
| P2093 | author name string | Katherine S Barker | |
| P David Rogers | |||
| Teresa T Liu | |||
| Julia BlaB-Warmuth | |||
| P2860 | cites work | CaIPF7817 is involved in the regulation of redox homeostasis in Candida albicans | Q80389170 |
| Heterozygosity of genes on the sex chromosome regulates Candida albicans virulence | Q80445106 | ||
| Cap1p is involved in multiple pathways of oxidative stress response in Candida albicans | Q82871230 | ||
| A common drug-responsive element mediates the upregulation of the Candida albicans ABC transporters CDR1 and CDR2, two genes involved in antifungal drug resistance | Q42673167 | ||
| Overexpression of the MDR1 gene is sufficient to confer increased resistance to toxic compounds in Candida albicans | Q43261180 | ||
| Molecular aspects of fluconazole resistance development in Candida albicans | Q43899356 | ||
| A proteomic approach to understanding the development of multidrug-resistant Candida albicans strains | Q44870226 | ||
| Sequential gene disruption in Candida albicans by FLP-mediated site-specific recombination | Q47965325 | ||
| A family of oligopeptide transporters is required for growth of Candida albicans on proteins | Q48090969 | ||
| The SAT1 flipper, an optimized tool for gene disruption in Candida albicans | Q48168925 | ||
| Targeted gene disruption in Candida albicans wild-type strains: the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates. | Q52539522 | ||
| Proteomic analysis of the oxidative stress response in Candida albicans. | Q53572547 | ||
| Identification of promoter elements responsible for the regulation of MDR1 from Candida albicans, a major facilitator transporter involved in azole resistance. | Q53583658 | ||
| Analysis of the oxidative stress regulation of the Candida albicans transcription factor, Cap1p. | Q54049038 | ||
| Protective effects of antioxidants against benomyl-induced lipid peroxidation and glutathione depletion in rats | Q73039998 | ||
| Identification of polymorphic mutant alleles of CaMDR1, a major facilitator of Candida albicans which confers multidrug resistance, and its in vitro transcriptional activation | Q77323771 | ||
| PDR16-mediated azole resistance in Candida albicans | Q79780176 | ||
| A human-curated annotation of the Candida albicans genome | Q21145286 | ||
| Involvement of yeast YOL151W/GRE2 in ergosterol metabolism | Q27930740 | ||
| Saccharomyces cerevisiae Hsp31p, a stress response protein conferring protection against reactive oxygen species | Q27933701 | ||
| Competitive promoter occupancy by two yeast paralogous transcription factors controlling the multidrug resistance phenomenon. | Q27936528 | ||
| A rapid and simple method for preparation of RNA from Saccharomyces cerevisiae | Q28131648 | ||
| Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals | Q28293585 | ||
| MDR1-mediated drug resistance in Candida dubliniensis | Q28364120 | ||
| TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. | Q33559776 | ||
| Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate | Q33630438 | ||
| Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents | Q33689421 | ||
| Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis | Q33701491 | ||
| Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. | Q33721804 | ||
| Drug-induced regulation of the MDR1 promoter in Candida albicans | Q33883805 | ||
| Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients | Q33983022 | ||
| The bZip transcription factor Cap1p is involved in multidrug resistance and oxidative stress response in Candida albicans | Q33991085 | ||
| The genetic basis of fluconazole resistance development in Candida albicans | Q34135429 | ||
| Endogenous reactive oxygen species is an important mediator of miconazole antifungal effect | Q34143941 | ||
| Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. | Q34417276 | ||
| Chromosome loss followed by duplication is the major mechanism of spontaneous mating-type locus homozygosis in Candida albicans | Q34572390 | ||
| A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans | Q34588684 | ||
| Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters | Q35120105 | ||
| Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors | Q35127954 | ||
| Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus | Q35137093 | ||
| Transcriptional regulation of MDR1, encoding a drug efflux determinant, in fluconazole-resistant Candida albicans strains through an Mcm1p binding site | Q35216756 | ||
| Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. | Q37091074 | ||
| Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. | Q37166301 | ||
| Comparison of gene expression profiles of Candida albicans azole-resistant clinical isolates and laboratory strains exposed to drugs inducing multidrug transporters | Q38338527 | ||
| Activation of the multiple drug resistance gene MDR1 in fluconazole-resistant, clinical Candida albicans strains is caused by mutations in a trans-regulatory factor | Q39498564 | ||
| Isogenic strain construction and gene targeting in Candida dubliniensis | Q39526406 | ||
| Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. | Q39559578 | ||
| Light-directed 5'-->3' synthesis of complex oligonucleotide microarrays | Q39744529 | ||
| The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans | Q39784510 | ||
| Overexpression of a cloned IMP dehydrogenase gene of Candida albicans confers resistance to the specific inhibitor mycophenolic acid | Q39845163 | ||
| Multiple cis-acting sequences mediate upregulation of the MDR1 efflux pump in a fluconazole-resistant clinical Candida albicans isolate | Q41473540 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Candida albicans | Q310443 |
| multiple drug resistance | Q643839 | ||
| P304 | page(s) | e164 | |
| P577 | publication date | 2007-11-01 | |
| P1433 | published in | PLOS Pathogens | Q283209 |
| P1476 | title | The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans | |
| P478 | volume | 3 |
| Q64915641 | A Hyperactive Form of the Zinc Cluster Transcription Factor Stb5 Causes YOR1 Overexpression and Beauvericin Resistance in Candida albicans. |
| Q93013988 | A New Age in Molecular Diagnostics for Invasive Fungal Disease: Are We Ready? |
| Q64118462 | A Potential Antifungal Effect of Chitosan Against Is Mediated via the Inhibition of SAGA Complex Component Expression and the Subsequent Alteration of Cell Surface Integrity |
| Q92282269 | A Systematic Screen Reveals a Diverse Collection of Medications That Induce Antifungal Resistance in Candida Species |
| Q93162239 | A Zinc Cluster Transcription Factor Contributes to the Intrinsic Fluconazole Resistance of Candida auris |
| Q36746995 | A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate. |
| Q54198368 | A pleiotropic drug resistance transporter is involved in reduced sensitivity to multiple fungicide classes in Sclerotinia homoeocarpa (F.T. Bennett). |
| Q36949532 | ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates. |
| Q42281238 | Amino acid-derived 1,2-benzisothiazolinone derivatives as novel small-molecule antifungal inhibitors: identification of potential genetic targets |
| Q33559158 | An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans |
| Q37417553 | An MDR1 promoter allele with higher promoter activity is common in clinically isolated strains of Candida albicans |
| Q89683135 | An Overview on Conventional and Non-Conventional Therapeutic Approaches for the Treatment of Candidiasis and Underlying Resistance Mechanisms in Clinical Strains |
| Q42708319 | An acquired mechanism of antifungal drug resistance simultaneously enables Candida albicans to escape from intrinsic host defenses. |
| Q48026484 | Analysis of a fungus-specific transcription factor family, the Candida albicans zinc cluster proteins, by artificial activation |
| Q98177626 | Antifungal Activity of the Natural Coumarin Scopoletin Against Planktonic Cells and Biofilms From a Multidrug-Resistant Candida tropicalis Strain |
| Q34086897 | Antifungal drug discovery: the process and outcomes |
| Q52652096 | Antifungal drug resistance: evolution, mechanisms and impact. |
| Q39751373 | Antifungal resistance and new strategies to control fungal infections |
| Q55378971 | Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia. |
| Q37580801 | Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species |
| Q48124370 | Azole resistance in Candida albicans from animals: Highlights on efflux pump activity and gene overexpression |
| Q90297410 | Candida Infections and Therapeutic Strategies: Mechanisms of Action for Traditional and Alternative Agents |
| Q92921364 | Candida albicans Antifungal Resistance and Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal |
| Q40093518 | Candida albicans Swi/Snf and Mediator Complexes Differentially Regulate Mrr1-induced MDR1 Expression and Fluconazole Resistance |
| Q91983100 | Candida parapsilosis: from Genes to the Bedside |
| Q33530441 | Changes in the proteome of Candida albicans in response to azole, polyene, and echinocandin antifungal agents |
| Q33668319 | Chemogenomic profiling predicts antifungal synergies. |
| Q92238742 | Comparative Genomics for the Elucidation of Multidrug Resistance in Candida lusitaniae |
| Q40230670 | Competitive Fitness of Fluconazole-Resistant Clinical Candida albicans Strains |
| Q33847058 | Contribution of CgPDR1-regulated genes in enhanced virulence of azole-resistant Candida glabrata |
| Q92127131 | Contribution of Clinically Derived Mutations in the Gene Encoding the Zinc Cluster Transcription Factor Mrr2 to Fluconazole Antifungal Resistance and CDR1 Expression in Candida albicans |
| Q37371189 | Coordinate control of lipid composition and drug transport activities is required for normal multidrug resistance in fungi. |
| Q47889156 | Cross-resistance to fluconazole induced by exposure to the agricultural azole tetraconazole: an environmental resistance school? |
| Q40045673 | Culture-Independent Molecular Methods for Detection of Antifungal Resistance Mechanisms and Fungal Identification |
| Q35748240 | Development of fluconazole resistance in a series of Candida parapsilosis isolates from a persistent candidemia patient with prolonged antifungal therapy |
| Q39537988 | Difference in virulence between fluconazole-susceptible and fluconazole-resistant Candida albicans in a mouse model |
| Q34932972 | Differential requirement of the transcription factor Mcm1 for activation of the Candida albicans multidrug efflux pump MDR1 by its regulators Mrr1 and Cap1. |
| Q34596791 | Disruption of the transcriptional regulator Cas5 results in enhanced killing of Candida albicans by Fluconazole |
| Q37545098 | Distinct roles of Candida albicans drug resistance transcription factors TAC1, MRR1, and UPC2 in virulence |
| Q38708362 | Drug resistance mechanisms and their regulation in non-albicans Candida species |
| Q37389756 | Efficient and rapid identification of Candida albicans allelic status using SNP-RFLP. |
| Q39021961 | Efflux as a mechanism of antimicrobial drug resistance in clinical relevant microorganisms: the role of efflux inhibitors |
| Q33474798 | Efflux in fungi: la pièce de résistance |
| Q59799244 | Efflux pump-mediated resistance to antifungal compounds can be prevented by conjugation with triphenylphosphonium cation |
| Q37156645 | Efflux-mediated antifungal drug resistance. |
| Q34419351 | Elucidating drug resistance in human fungal pathogens |
| Q26750816 | Emerging Threats in Antifungal-Resistant Fungal Pathogens |
| Q38711698 | Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus. |
| Q64900635 | Evidence that Ergosterol Biosynthesis Modulates Activity of the Pdr1 Transcription Factor in Candida glabrata. |
| Q64274667 | Evolution of Fluconazole-Resistant Candida albicans Strains by Drug-Induced Mating Competence and Parasexual Recombination |
| Q58618058 | Evolution of drug resistance in an antifungal-naive chronic infection |
| Q57154621 | Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens |
| Q38060200 | Exploitation of genomics in fungicide research: current status and future perspectives |
| Q37629735 | Extensive functional redundancy in the regulation of Candida albicans drug resistance and morphogenesis by lysine deacetylases Hos2, Hda1, Rpd3 and Rpd31. |
| Q39092120 | Fluconazole resistance in Candida species: a current perspective |
| Q42735156 | Fluconazole transport into Candida albicans secretory vesicles by the membrane proteins Cdr1p, Cdr2p, and Mdr1p |
| Q35191806 | Functional dissection of a Candida albicans zinc cluster transcription factor, the multidrug resistance regulator Mrr1. |
| Q28472187 | Fungicide-driven evolution and molecular basis of multidrug resistance in field populations of the grey mould fungus Botrytis cinerea |
| Q36362353 | Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans |
| Q36993519 | Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains |
| Q30434904 | Genetic Basis of Antifungal Drug Resistance |
| Q33768787 | Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection |
| Q36302129 | Genome-wide functional analysis in Candida albicans. |
| Q37175383 | Genome-wide mapping of the coactivator Ada2p yields insight into the functional roles of SAGA/ADA complex in Candida albicans |
| Q38292045 | Genomewide location analysis of Candida albicans Upc2p, a regulator of sterol metabolism and azole drug resistance |
| Q28539336 | Glutathione metabolism in Candida albicans resistant strains to fluconazole and micafungin |
| Q35746841 | High-Resolution SNP/CGH Microarrays Reveal the Accumulation of Loss of Heterozygosity in Commonly Used Candida albicans Strains |
| Q90028212 | Host-Pathogen Interactions Mediated by MDR Transporters in Fungi: As Pleiotropic as it Gets! |
| Q42271039 | Identification and functional characterization of Rca1, a transcription factor involved in both antifungal susceptibility and host response in Candida albicans |
| Q37232388 | Identification of the Candida albicans Cap1p regulon. |
| Q92613690 | In Vitro Activities of the Novel Investigational Tetrazoles VT-1161 and VT-1598 Compared to the Triazole Antifungals against Azole-Resistant Strains and Clinical Isolates of Candida albicans |
| Q42280706 | Inducible and constitutive activation of two polymorphic promoter alleles of the Candida albicans multidrug efflux pump MDR1. |
| Q43102374 | Induction of Candida albicans drug resistance genes by hybrid zinc cluster transcription factors |
| Q36267962 | Inhibitory activity of hinokitiol against biofilm formation in fluconazole-resistant Candida species |
| Q34572537 | Intra-platform comparison of 25-mer and 60-mer oligonucleotide Nimblegen DNA microarrays |
| Q64120011 | Linking Cellular Morphogenesis with Antifungal Treatment and Susceptibility in Pathogens |
| Q57461257 | Loss of C-5 sterol desaturase activity in - azole resistance or merely trailing growth? |
| Q54201991 | Loss of Upc2p-Inducible ERG3 Transcription Is Sufficient To Confer Niche-Specific Azole Resistance without Compromising Candida albicans Pathogenicity. |
| Q42164809 | Loss of heterozygosity at an unlinked genomic locus is responsible for the phenotype of a Candida albicans sap4Δ sap5Δ sap6Δ mutant |
| Q38836667 | MFS transporters of Candida species and their role in clinical drug resistance. |
| Q38266675 | Mechanisms of Antifungal Drug Resistance |
| Q37762556 | Mechanisms of antifungal drug resistance in Candida dubliniensis |
| Q38559208 | Medically important fungi respond to azole drugs: an update. |
| Q64239859 | Microevolution of the pathogenic yeasts and during antifungal therapy and host infection |
| Q36558410 | Milbemycins: more than efflux inhibitors for fungal pathogens |
| Q36969703 | Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals |
| Q46324582 | Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans |
| Q36076001 | Multidrug Transporters and Alterations in Sterol Biosynthesis Contribute to Azole Antifungal Resistance in Candida parapsilosis |
| Q38209314 | Multidrug resistance in fungi: regulation of transporter-encoding gene expression |
| Q34991073 | Multidrug-resistant transporter mdr1p-mediated uptake of a novel antifungal compound |
| Q37183937 | Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains |
| Q46974370 | Networks of genes modulating the pleiotropic drug response in Saccharomyces cerevisiae |
| Q38155848 | Novel Regulatory Mechanisms of Pathogenicity and Virulence to Combat MDR in Candida albicans |
| Q33746435 | Oropharyngeal candidiasis in the era of antiretroviral therapy |
| Q91739554 | Ospemifene displays broad-spectrum synergistic interactions with itraconazole through potent interference with fungal efflux activities |
| Q43048723 | Overexpression of CDR1 and CDR2 genes plays an important role in fluconazole resistance in Candida albicans with G487T and T916C mutations |
| Q40045106 | Parasex Generates Phenotypic Diversity de Novo and Impacts Drug Resistance and Virulence in Candida albicans |
| Q39279261 | Persistent Candida albicans colonization and molecular mechanisms of azole resistance in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients. |
| Q41560130 | Proteomic analysis of Mrr1p- and Tac1p-associated differential protein expression in azole-resistant clinical isolates of Candida albicans |
| Q90706918 | Quantitative analysis of the expression of fluconazole-resistant genes in strains of Candida albicans isolated from elderly people at their admission in an intensive care unit in Manizales, Colombia |
| Q37271658 | Quinone derivatives isolated from the endolichenic fungus Phialocephala fortinii are Mdr1 modulators that combat azole resistance in Candida albicans |
| Q34932227 | Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicans |
| Q34190284 | Regulatory circuitry governing fungal development, drug resistance, and disease. |
| Q37144914 | Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance |
| Q46247342 | Repurposing an inhibitor of ribosomal biogenesis with broad anti-fungal activity |
| Q94554889 | Repurposing approach identifies pitavastatin as a potent azole chemosensitizing agent effective against azole-resistant Candida species |
| Q50054211 | Research of Mrr1, Cap1 and MDR1 in Candida albicans resistant to azole medications |
| Q28472787 | Reverse genetics in Candida albicans predicts ARF cycling is essential for drug resistance and virulence |
| Q36990987 | Reversion of a fungal genetic code alteration links proteome instability with genomic and phenotypic diversification |
| Q92071802 | Review on Antifungal Resistance Mechanisms in the Emerging Pathogen Candida auris |
| Q37301928 | Role of Ndt80p in sterol metabolism regulation and azole resistance in Candida albicans. |
| Q34057364 | SAGA/ADA complex subunit Ada2 is required for Cap1- but not Mrr1-mediated upregulation of the Candida albicans multidrug efflux pump MDR1 |
| Q37122826 | Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance |
| Q41442442 | Synergistic and drug-resistant reversing effects of diorcinol D combined with fluconazole against Candida albicans |
| Q28539874 | Systematic phenotyping of a large-scale Candida glabrata deletion collection reveals novel antifungal tolerance genes |
| Q92353496 | The Impact of Gene Dosage and Heterozygosity on The Diploid Pathobiont Candida albicans |
| Q38752384 | The development of fluconazole resistance in Candida albicans - an example of microevolution of a fungal pathogen |
| Q38009721 | The effect of biomaterials and antifungals on biofilm formation by Candida species: a review |
| Q37075845 | The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. |
| Q39092291 | The global problem of antifungal resistance: prevalence, mechanisms, and management |
| Q28477254 | The transcription factor Ndt80 does not contribute to Mrr1-, Tac1-, and Upc2-mediated fluconazole resistance in Candida albicans |
| Q35960980 | Transcription factor ADS-4 regulates adaptive responses and resistance to antifungal azole stress |
| Q28079641 | Transcriptional Control of Drug Resistance, Virulence and Immune System Evasion in Pathogenic Fungi: A Cross-Species Comparison |
| Q42110990 | Transcriptional profiling of azole-resistant Candida parapsilosis strains |
| Q90000743 | Trichophyton rubrum Azole Resistance Mediated by a New ABC Transporter, TruMDR3 |
| Q92608570 | Two natural molecules preferentially inhibit azole-resistant Candida albicans with MDR1 hyperactivation |
| Q34057076 | UPC2 is universally essential for azole antifungal resistance in Candida albicans |
| Q41135029 | Update on Antifungal Drug Resistance |
| Q41600855 | Virulence factors, antifungal susceptibility and molecular mechanisms of azole resistance among Candida parapsilosis complex isolates recovered from clinical specimens |
| Q38696236 | Vulvovaginal candidosis: contemporary challenges and the future of prophylactic and therapeutic approaches. |
| Q28834633 | Xenobiotic efflux in bacteria and fungi: a genomics update |
| Q28481716 | Yeasts acquire resistance secondary to antifungal drug treatment by adaptive mutagenesis |
| Q41520257 | miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression |
Search more.